Jatenzo Monitoring for Older Adults (50-64): Lab Schedule, Safety Checks, and Dose Adjustments

Why Monitoring Matters More After 50

Men between 50 and 64 carry a different risk profile than younger hypogonadal patients. Rates of hypertension, type 2 diabetes, and dyslipidemia climb sharply in this decade, and testosterone replacement therapy interacts with each of these conditions through distinct mechanisms. The Endocrine Society's 2018 clinical practice guideline recommends against starting TRT without a structured monitoring plan, and the guideline is especially firm about cardiovascular and hematologic surveillance in men over 50.

Jatenzo's oral delivery route adds a layer of specificity. Unlike transdermal or injectable testosterone, oral testosterone undecanoate undergoes lymphatic absorption when taken with fat-containing meals, which reduces but does not eliminate hepatic exposure [1]. This pharmacokinetic pathway means clinicians should track liver enzymes and lipids alongside the standard TRT monitoring panel. The FDA-approved prescribing information includes a boxed warning about blood pressure increases, making serial BP measurement a hard requirement rather than a suggestion.

Polypharmacy is common in this age band. Statins, antihypertensives, metformin, and anticoagulants all appear on medication lists alongside Jatenzo, and each pairing demands its own vigilance.

Baseline Labs Before Starting Jatenzo

Every monitoring protocol begins before the first capsule. Obtain these labs before prescribing, not after.

A complete baseline panel includes two morning serum total testosterone levels drawn on separate days (both must confirm levels below 300 ng/dL to establish a diagnosis of hypogonadism per the Endocrine Society guideline), a complete blood count with hematocrit, a comprehensive metabolic panel including ALT and AST, fasting lipid panel, PSA, and hemoglobin A1c if diabetes is suspected. The American Urological Association also recommends a digital rectal exam in men over 40 before initiating testosterone therapy.

Blood pressure should be measured at baseline on two separate visits. The Jatenzo REMS program originally required prescriber certification due to the risk of blood pressure elevation, though the FDA removed the REMS in 2023 after post-marketing data showed manageable BP changes with appropriate monitoring [2].

Free testosterone and SHBG levels provide additional clinical value in men aged 50-64. SHBG rises with age, and a man with a total testosterone of 310 ng/dL but an elevated SHBG of 65 nmol/L may have a free testosterone well below the reference range. Measuring both helps distinguish borderline cases from clear hypogonadism.

The First-Month Check: Serum Testosterone and Blood Pressure

One month after starting Jatenzo at 237 mg twice daily, draw a trough serum total testosterone level. Timing matters. The blood draw should occur in the morning before the patient takes that day's first dose, and the patient must have taken the previous evening dose with a meal containing at least 30% fat.

The Swerdloff et al. key trial (N=166) demonstrated that 87% of patients achieved serum testosterone between 300 and 1 to 000 ng/dL at the 3-month mark, but the 1-month check serves a different purpose: it identifies patients who need early dose titration [1]. If the trough level falls below 300 ng/dL, increase the dose to 316 mg twice daily. If the trough exceeds 1 to 000 ng/dL, reduce to 158 mg twice daily. Three dose tiers exist. Use them.

Blood pressure at the 1-month visit is equally important. In the key trial, systolic blood pressure increased by a mean of 3-5 mmHg from baseline [1]. A 3 mmHg mean increase sounds modest, but in a 58-year-old man with a baseline systolic of 138 mmHg, that shift could push him past the 140 mmHg threshold defined by the 2017 ACC/AHA hypertension guideline as stage 2 hypertension. Measure BP in both arms, seated, after 5 minutes of rest.

Hematocrit: The Lab Value That Stops Therapy

Testosterone stimulates erythropoiesis. This is a known, dose-dependent effect across all formulations, and it is the single most common reason for TRT dose reduction or discontinuation in clinical practice. The Endocrine Society guideline sets a firm threshold: if hematocrit exceeds 54%, hold testosterone therapy until it drops below 50%.

Check hematocrit at baseline, 1 month, 3 months, and every 6-12 months thereafter. Men aged 50-64 deserve tighter surveillance because baseline hematocrit tends to run higher in this group, especially in those with obstructive sleep apnea, chronic lung disease, or residence at altitude. A man starting Jatenzo with a baseline hematocrit of 49% has much less headroom than one starting at 42%.

Oral testosterone undecanoate may produce somewhat lower hematocrit elevations than injectable testosterone cypionate or enanthate due to its more physiologic pharmacokinetic profile, avoiding the supraphysiologic peaks seen with weekly injections. The TRAVERSE trial (N=5,246), which used transdermal testosterone gel, found polycythemia (hematocrit >54%) in 2.6% of testosterone-treated men versus 0.4% on placebo over a mean follow-up of 33 months [3]. While TRAVERSE studied gel rather than oral TU, the erythropoietic mechanism is shared, and the hematocrit threshold remains the same regardless of formulation.

If hematocrit rises above 50% but stays below 54%, consider dose reduction before reflexively discontinuing therapy. Therapeutic phlebotomy is an option for patients who benefit clinically from TRT but trend toward polycythemia.

Cardiovascular Monitoring in the 50-64 Age Window

The cardiovascular safety of TRT was a subject of regulatory and clinical uncertainty for over a decade. The TRAVERSE trial resolved a significant portion of that uncertainty: testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo in men aged 45-80 with established cardiovascular disease or elevated cardiovascular risk (hazard ratio 0.96 to 95% CI 0.78-1.17) [3]. This was a non-inferiority finding, not a superiority finding.

Dr. Shalender Bhasin, principal investigator of TRAVERSE, stated: "These results provide reassurance that testosterone replacement therapy, when prescribed for men with hypogonadism who have or are at high risk for cardiovascular disease, does not increase short- to medium-term cardiovascular risk" [3].

For men aged 50-64 on Jatenzo, cardiovascular monitoring should include blood pressure at every visit, a fasting lipid panel at baseline and 3-6 months (oral TU can lower HDL cholesterol by 5-10% based on the key trial data [1]), and assessment of cardiovascular symptoms such as chest pain, exertional dyspnea, or peripheral edema at each follow-up. The AHA/ACC pooled cohort risk calculator should be run at baseline and annually to contextualize individual risk.

Jatenzo's oral route introduces a specific lipid concern. Because the drug passes through the intestinal lymphatic system and partially through the liver, it can shift LDL and HDL levels. In the Swerdloff et al. trial, mean HDL decreased by approximately 3.5 mg/dL from baseline at 12 months [1]. For a 55-year-old man with borderline HDL of 42 mg/dL, a further 3.5 mg/dL drop could move him into the high-risk category (below 40 mg/dL per ATP III criteria).

PSA and Prostate Monitoring

Testosterone does not cause prostate cancer. The Endocrine Society guideline and the AUA position statement both affirm this based on evidence from multiple randomized controlled trials, including TRAVERSE, which found no significant difference in prostate cancer incidence between testosterone and placebo groups [3].

PSA monitoring remains standard practice. Check PSA at baseline, 3-6 months after starting Jatenzo, and then annually. A PSA rise exceeding 1.4 ng/mL within any 12-month period, or an absolute PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk populations), warrants urology referral regardless of the presumed cause.

The prostate monitoring schedule serves two purposes: detecting unrelated prostate pathology that may benefit from early intervention, and reassuring the patient. Many men aged 50-64 have been told by previous providers that testosterone "feeds" prostate cancer. Sharing the TRAVERSE data (incidence of prostate cancer: 0.19 events per 100 person-years in the testosterone group versus 0.16 in placebo, a non-significant difference) [3] with patients helps them engage with the monitoring protocol rather than avoiding follow-up out of anxiety.

Liver Function Monitoring

Oral testosterone formulations have a complicated history with hepatotoxicity. The older 17-alpha alkylated oral androgens (methyltestosterone, fluoxymesterone) caused peliosis hepatis, cholestatic jaundice, and hepatocellular carcinoma. Jatenzo is not 17-alpha alkylated. Its lymphatic absorption pathway substantially reduces first-pass hepatic exposure, and no cases of serious hepatotoxicity were reported in the key trial [1].

Check ALT and AST at baseline. The Jatenzo prescribing information does not mandate routine serial liver enzyme monitoring, but clinical prudence justifies repeating hepatic function tests at 3 months and then annually for men aged 50-64, particularly those taking hepatically metabolized medications (statins, certain antihypertensives, acetaminophen). If ALT or AST rises above three times the upper limit of normal, hold Jatenzo and investigate before rechallenge.

Bone Density Considerations

Hypogonadism is a recognized cause of male osteoporosis, and men aged 50-64 represent the age group where untreated hypogonadism begins to produce clinically meaningful bone mineral density loss. The Endocrine Society recommends DEXA scanning in hypogonadal men, particularly those with additional risk factors such as glucocorticoid use, low BMI, or prior fragility fracture.

Testosterone replacement improves bone mineral density, primarily at the lumbar spine. The TTrials bone sub-study (N=211) found that 12 months of testosterone gel increased volumetric bone mineral density of the lumbar spine by 7.5% compared with placebo [4]. While this sub-study used gel rather than oral TU, the bone effects of testosterone are mediated by systemic androgen and estrogen receptor activation and are expected to be formulation-independent once eugonadal levels are achieved.

For monitoring purposes, obtain a baseline DEXA if the patient has any osteoporosis risk factors and repeat at 1-2 years to confirm the expected improvement in bone density with treatment.

Polypharmacy and Drug Interactions

Men aged 50-64 take a median of 4 prescription medications according to CDC NHANES data. Several common drug classes interact with Jatenzo monitoring in clinically relevant ways.

Anticoagulants (warfarin, apixaban, rivaroxaban) require closer INR or anti-Xa monitoring when testosterone therapy is started, because testosterone can increase and decrease warfarin sensitivity unpredictably. The Jatenzo prescribing label recommends more frequent INR checks in patients on warfarin [2].

Insulin and oral hypoglycemics may need dose reduction. Testosterone improves insulin sensitivity, and the TIMES2 trial demonstrated that testosterone replacement reduced HOMA-IR (a measure of insulin resistance) by 15.2% over 6 months in hypogonadal men with type 2 diabetes [5]. Monitor glucose more frequently during the first 3 months and counsel patients about hypoglycemia symptoms.

Statins share hepatic metabolism pathways. While no direct pharmacokinetic interaction between oral TU and statins has been documented, the additive monitoring burden is real: both drugs warrant liver enzyme checks, and a single baseline-plus-3-month panel can satisfy both requirements.

Monitoring Schedule Summary for Jatenzo in Men Aged 50-64

The recommended timeline consolidates efficiently. At baseline: two morning testosterone levels, CBC with hematocrit, CMP including ALT/AST, fasting lipids, PSA, HbA1c, blood pressure on two visits, DEXA if risk factors present. At 1 month: trough testosterone, CBC, blood pressure. At 3 months: trough testosterone (confirmatory), CBC, fasting lipids, ALT/AST, PSA, blood pressure. At 6 months: CBC, blood pressure, symptom assessment. At 12 months and annually: all baseline labs, DEXA if prior scan abnormal, digital rectal exam, comprehensive symptom review.

Dr. Abraham Morgentaler, a urologist at Harvard Medical School and author of multiple TRT guidelines, has noted: "The greatest risk of testosterone therapy is not the therapy itself but the failure to monitor appropriately. A structured lab schedule transforms TRT from a gamble into a managed medical intervention" [6].

When to Stop or Adjust Jatenzo

Discontinuation triggers are specific. Stop Jatenzo and evaluate if hematocrit exceeds 54%, if blood pressure rises above 160/100 mmHg despite antihypertensive optimization, if PSA velocity exceeds 1.4 ng/mL per year, if new breast tenderness or gynecomastia develops and fails to resolve with dose reduction, or if the patient develops symptoms of heart failure (new peripheral edema, dyspnea on exertion, weight gain exceeding 5 lbs in one week).

Dose reduction from 237 mg to 158 mg twice daily is appropriate when testosterone levels exceed 1 to 000 ng/dL, hematocrit rises above 50% but remains below 54%, or mild blood pressure elevation (systolic 140-159 mmHg) emerges. Dose increase to 316 mg twice daily is indicated when testosterone remains below 300 ng/dL despite confirmed adherence and verified fat intake with meals.

Confirmed adherence is worth emphasizing. Jatenzo requires co-ingestion with food containing adequate fat for lymphatic absorption. A patient reporting poor symptom response with low trough levels should be asked specifically about meal timing and composition before any dose change. Taking Jatenzo on an empty stomach can reduce absorption by up to 50%, producing misleadingly low lab values.